Table 3.
Oncolytic vaccinia virus (VACV) developed for cancer treatment.
| Virus | Target Cancer | Features | Reference | |
|---|---|---|---|---|
| Inactive Genes | Additional Genes | |||
| Initial virus | ||||
| JX-594 | Melanoma, hepatocellular carcinoma, colorectal cancer | TK inactive, | LacZ and GM-CSF | [112,114] |
| GLV-1h68 | Colorectal cancer, prostate cancer, salivary gland carcinoma | TK, HA and F14.5L inactive | GFP, LacZ and GUS | [111] |
| vvDD | Sarcomas, neuroblastoma | TK and VGF inactive | CD | [115,116] |
| Enhanced virus | ||||
| GLV-1h153 | Pancreatic cancer | GLV-1h68 expressing hNIS | [110] | |
| GLV-1h210 | Lung cancer | GLV-1h68 expressing hEPO | [117] | |
| vvDD-SR-RFP | Sarcomas, neuroblastoma | TK and VGF inactive | CD, RFP, SR | [118] |